Skip to content
2000
Volume 6, Issue 2
  • ISSN: 1872-3128
  • E-ISSN: 1874-0758

Abstract

m-Hydroxymexiletine (MHM), a minor metabolite of the class IB anti-arrhythmic drug mexiletine, is about two fold more potent than the parent compound on human cardiac voltage-gated sodium channels (hNav1.5), and equipotent to mexiletine on human skeletal-muscle voltage-gated sodium channels (hNav1.4). Herein, an alternative and simplified synthesis of this promising compound has been accomplished. This route, as well as being more efficient, has the advantage, over the first, to avoid the use of oxidizing agents, such as the meta-chloroperoxybenzoic acid.

Loading

Article metrics loading...

/content/journals/dml/10.2174/187231212804096691
2012-06-01
2025-12-13
Loading full text...

Full text loading...

/content/journals/dml/10.2174/187231212804096691
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test